title: VLDL receptor mediates the uptake of human chylomicron remnants in vitro.
abstract: The VLDL receptor has been described as a new member of the LDL receptor supergene family that specifically binds VLDL in vitro via apolipoprotein E and lipoprotein lipase. Both apolipoprotein E and lipoprotein lipase are constituents of chylomicron remnants, another triglyceride-rich lipoprotein which has been proposed as a physiological ligand for the VLDL receptor. We used human chylomicron remnants to study their uptake into LDL, receptor-deficient Chinese hamster ovary cells overexpressing the human VLDL receptor. The uptake into these cells was compared to that into cells transfected with an empty transfection vector. Human chylomicron remnants were produced in vitro by hydrolysis with lipoprotein lipase, and were labeled with 125I. The uptake of these remnants into the cells overexpressing the VLDL receptor was found to be about 3-fold higher than the uptake into the control cells. The addition of a surplus of either apolipoprotein E or inactivated lipoprotein lipase to the remnants led to an increase in particle uptake. The chylomicron remnant uptake was inhibited by addition of the 39 kDa receptor associated protein These in vitro experiments strongly support the idea that the VLDL receptor is a physiological receptor for chylomicron remnants. The increase of receptor-mediated uptake induced by the addition of apoE or lipoprotein lipase underlines the role of these two proteins in this process.
authors.affiliation: Medizinische Klinik, Universitätskrankenhaus Eppendorf, Hamburg, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Niemeier
authors.forename: M
authors.initials: M
authors.lastname: Gàfvels
authors.forename: J
authors.initials: J
authors.lastname: Heeren
authors.forename: N
authors.initials: N
authors.lastname: Meyer
authors.forename: B
authors.initials: B
authors.lastname: Angelin
authors.forename: U
authors.initials: U
authors.lastname: Beisiegel
mesh_terms: D000818:Animals; D001057:Apolipoproteins E / Q000494:pharmacology; D015153:Blotting, Western; D016466:CHO Cells; D002352:Carrier Proteins / Q000494:pharmacology; D002914:Chylomicrons / Q000378:metabolism*; D006224:Cricetinae; D004591:Electrophoresis, Polyacrylamide Gel; D005786:Gene Expression Regulation / Q000235:genetics*; D006023:Glycoproteins / Q000494:pharmacology; D006801:Humans; D007457:Iodine Radioisotopes; D026563:LDL-Receptor Related Protein-Associated Protein; D008024:Ligands; D008071:Lipoprotein Lipase / Q000494:pharmacology; D008079:Lipoproteins, VLDL / Q000032:analysis / Q000378:metabolism*; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism*; D011817:Rabbits; D011973:Receptors, LDL / Q000235:genetics / Q000378:metabolism*; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism
chemical_list: D001057:Apolipoproteins E; D002352:Carrier Proteins; D002914:Chylomicrons; D006023:Glycoproteins; D007457:Iodine Radioisotopes; D026563:LDL-Receptor Related Protein-Associated Protein; D008024:Ligands; D008079:Lipoproteins, VLDL; D008565:Membrane Proteins; D011973:Receptors, LDL; D011994:Recombinant Proteins; C036053:VLDL receptor; D008071:Lipoprotein Lipase